• Explore /
  • Poster
  • / Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).

Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).

Abstract Poster

Authors

null

Orazio Caffo

Santa Chiara Hospital, Trento, Italy

Orazio Caffo , Michel Wissing , Diletta Bianchini , Andre M. Bergman , Frederik Birkebæk Thomsen , Sebastian Schmid , Evan Y. Yu , Evangelos Bournakis , Avishay Sella , Umberto Basso , Ugo De Giorgi , Marcello Tucci , Hans Gelderblom , Luca Galli , Isabella Sperduti , Stephane Oudard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5026)

DOI

10.1200/JCO.2018.36.15_suppl.5026

Abstract #

5026

Poster Bd #

253

Abstract Disclosures

Similar Posters

First Author: Celestia S. Higano

First Author: Darren M.C. Poon

First Author: Orazio Caffo

First Author: Orazio Caffo